Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS …
…, S Fairbairn, H Ghani, EA Gorman, CA Green… - Jama, 2022 - jamanetwork.com
Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO)
have been recommended for acute hypoxemic respiratory failure in patients with COVID-19…
have been recommended for acute hypoxemic respiratory failure in patients with COVID-19…
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
…, A Ustianowski, E Elmahi, B Prudon, C Green… - MedRxiv, 2020 - medrxiv.org
Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Objective To characterise the clinical features of patients admitted to hospital with coronavirus
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
…, K Dodd, Y Enever, K Gokani, AL Goodman, CA Green… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C …
Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
Advanced technology paths to global climate stability: energy for a greenhouse planet
MI Hoffert, K Caldeira, G Benford, DR Criswell, C Green… - science, 2002 - science.org
Stabilizing the carbon dioxide–induced component of climate change is an energy problem.
Establishment of a course toward such stabilization will require the development within the …
Establishment of a course toward such stabilization will require the development within the …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
